Insmed Incorporated (NASDAQ:INSM) CEO Sells $542,552.36 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 8,218 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $66.02, for a total value of $542,552.36. Following the sale, the chief executive officer now directly owns 376,742 shares in the company, valued at approximately $24,872,506.84. The trade was a 2.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Price Performance

INSM opened at $65.25 on Friday. The company’s 50-day simple moving average is $71.23 and its two-hundred day simple moving average is $72.42. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The stock has a market capitalization of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) EPS. The company’s revenue was up 18.1% compared to the same quarter last year. As a group, analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Analyst Ratings Changes

INSM has been the subject of a number of recent research reports. Bank of America lifted their price target on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. upped their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Trading of Insmed

Several large investors have recently modified their holdings of INSM. V Square Quantitative Management LLC bought a new position in Insmed in the third quarter valued at about $30,000. GAMMA Investing LLC increased its position in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the period. Blue Trust Inc. boosted its holdings in shares of Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 1,879 shares during the last quarter. Finally, JCIC Asset Management Inc. purchased a new position in shares of Insmed in the third quarter worth approximately $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.